B cell depletion in autoimmune rheumatic diseases

被引：21
作者：
Pitashny, M
Shoenfeld, Y
机构：
[1] Chaim Sheba Med Ctr, Dept Internal Med B, IL-52621 Tel Hashomer, Israel
[2] Chaim Sheba Med Ctr, Ctr Autoimmune Dis, IL-52621 Tel Hashomer, Israel
[3] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[4] Tel Aviv Univ, Incumbent Laura Schwarz Kipp Chair Res Autoimmune, IL-69978 Tel Aviv, Israel
来源：
AUTOIMMUNITY REVIEWS | 2005年 / 4卷 / 07期
关键词：
anti-CD20; rituximab; autoimmune diseases; B cell depletion;
D O I：
10.1016/j.autrev.2005.03.002
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Rituximab is a chimeric mouse-human monoclonal antibody, which binds to CD20, a B cell surface marker, leading to cell death by complement induced lysis and apoptosis. Since the introduction of this drug in the treatment of non-Hodgkin lymphoma, its applications have been extended to autoimmune diseases. This review summarizes the actual possible uses of this novel immune system targeted drug, and explains the mechanism of B cell depletion in autoimmune diseases. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码：436 / 441
页数：6
相关论文
共 22 条
  • [11] Rituximab chimeric Anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma:: Half of patients respond to a four-dose treatment program
    McLaughlin, P
    Grillo-López, AJ
    Link, BK
    Levy, R
    Czuczman, MS
    Williams, ME
    Heyman, MR
    Bence-Bruckler, I
    White, CA
    Cabanillas, F
    Jain, V
    Ho, AD
    Lister, J
    Wey, K
    Shen, D
    Dallaire, BK
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) : 2825 - 2833
  • [12] Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis
    Monson, NL
    Cravens, PD
    Frohman, EM
    Hawker, K
    Racke, MK
    [J]. ARCHIVES OF NEUROLOGY, 2005, 62 (02) : 258 - 264
  • [13] Panayi GS, 2005, J RHEUMATOL, V32, P19
  • [14] Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus
    Perrotta, S
    Locatelli, F
    La Manna, A
    Cennamo, L
    De Stefano, P
    Nobili, B
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2002, 116 (02) : 465 - 467
  • [15] Treatment of IgM antibody associated polyneuropathies using rituximab
    Pestronk, A
    Florence, J
    Miller, T
    Choksi, R
    Al-Lozi, MT
    Levine, TD
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2003, 74 (04) : 485 - 489
  • [16] Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg
    Rüegg, SJ
    Fuhr, P
    Steck, AJ
    [J]. NEUROLOGY, 2004, 63 (11) : 2178 - 2179
  • [17] Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand - An open-label trial
    Sfikakis, PP
    Boletis, JN
    Lionaki, S
    Vigklis, V
    Fragiadaki, KG
    Iniotaki, A
    Moutsopoulos, HM
    [J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (02): : 501 - 513
  • [18] Autoantibody explosion in systemic lupus erythematosus: More than 100 different antibodies found in SLE patients
    Sherer, Y
    Gorstein, A
    Fritzler, MJ
    Shoenfeld, Y
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2004, 34 (02) : 501 - 537
  • [19] Rituximab and Wegener's granulomatosis: Are B cells a target in vasculitis treatment?
    Sneller, MC
    [J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (01): : 1 - 5
  • [20] Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura
    Stasi, R
    Pagano, A
    Stipa, E
    Amadori, S
    [J]. BLOOD, 2001, 98 (04) : 952 - 957
123